SPONSOR
Eben Rosenthal
Total Trials
2
Recruiting
2
Phases
EARLY_Phase 1
Conditions studied: Brain CancerHGGGliomaHigh Grade GliomaHigh Grade GliomasHigh Grade Glioma (III or IV)High Grade Glioma (HGG) of the Brain With BRAF AberrationMeningiomaGlioblastomaAcoustic Neuroma
Eben Rosenthal is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Brain Cancer, HGG, Glioma, High Grade Glioma.
The trial portfolio spans EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Eben Rosenthal
How many clinical trials has Eben Rosenthal sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Eben Rosenthal, of which 2 are actively recruiting participants. These trials cover conditions including Brain Cancer, HGG, Glioma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Eben Rosenthal research focus on?
Eben Rosenthal clinical trials span Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, and additional conditions. The research pipeline includes EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Eben Rosenthal clinical trial?
To participate in a Eben Rosenthal trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Eben Rosenthal trials with current recruitment status updated daily.
Clinical Trials by Eben Rosenthal
NCT07210632 EARLY_Phase 1
Recruiting
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
Brain Cancer
NCT07493447 EARLY_Phase 1
Recruiting
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Meningioma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology